I would like you to perform a ratio analysis on the financial statements. You will want to compute ratios for your company for the last two years. Do not compute each ratio you learned about for your company. There may be some that are not relevant. Rather focus on those eight ratios that you feel are the most important and relevant to analyze how your company is doing.
Year ended December 31, 2017 2016 2018 1 2015 2014 15 964 6956 11 836 110 000 807 9 485 6 867 11 856 104 871 7777 5 447 13 862 62556 2266 093 10 899 11 172 10 805 105 193 108 711 87 826 (USD millions) BALANCE SHEET DATA Cash, cash equivalents and marketable securities & derivative financial instruments Inventories Other current assets Non-current assets Assets of disposal group held for sale Assets related to discontinued operations Total assets Trade accounts payable Other current liabilities Non-current liabilities Liabilities of disposal group held for sale Liabilities related to discontinued operations Total liabilities Issued share capital and reserves attributable to shareholders of Novartis AG Non-controlling interests Total equity Total liabilities and equity Net assets Outstanding share capital Total outstanding shares (millions) 145 563 5 556 24 000 37 264 51 133 079 5 169 18 234 35 449 130 124 4873 17 336 33 024 131 556 5668 18 040 30 726 6 801 125 387 5 419 19 136 27 570 2418 54 543 66 871 58 852 55 233 54 434 78 614 78 78 692 145 563 78 692 875 2 311 74 168 59 74 227 133 079 74 227 869 2317 74 832 59 74 891 130 124 74 891 896 2 374 77 046 76 77 122 131 556 77 122 890 2374 70 766 78 70 844 125 387 70 844 898 2 399 The disposal group held for sale relate to the assets and liabilities of the pending divestment of the Sandoz US dermatology business and generic US oral solids portfolio to Aurobindo Pharma USA Inc., as announced on September 6, 2018 (see "item 18. Financial Statements - Note 2 Significant pending transactions). ? A description of discontined operations can be found in footnote 1 of the table above. Year ended December 31, 2017 2016 2018 2015 2014 (USD millions, except per share information) INCOME STATEMENT DATA Net sales to third parties from continuing operations Operating income from continuing operations Income from associated companies Interest expense Other financial income and expense Income before taxes from continuing operations Taxes Net income from continuing operations Net income/(loss) from discontinued operations Group net income Attributable to: Shareholders of Novartis AG Non-controlling interests 51 900 8 169 6 438 -957 185 13 835 - 1 221 12 614 49 109 8 629 1 108 - 777 3 9 999 - 1 296 7 703 48 518 8 268 703 - 707 -447 7 817 - 1 119 6698 49 414 8977 266 - 655 - 454 8 134 - 1 106 7028 10 766 17 794 52 180 11 089 1918 -704 - 31 12 272 - 1545 10 727 - 447 10 280 8 12 614 7 703 6698 12 611 - 3 7703 o 6 712 -14 17783 11 10 210 70 5.44 3.28 2.82 2.92 Basic earnings per share (USD) Continuing operations Discontinued operations Total 4.48 7.40 4.39 -0.18 4.21 5.44 3.28 2.82 5.38 3.25 2.80 7.29 Diluted earnings per share (USD) Continuing operations Discontinued operations Total Cash dividends Cash dividends per share in CHF3 Personnel cost45 Full-time equivalent associates at year-ends 5.38 6966 2.85 15 651 125 161 3.25 6 495 2.80 13 932 121 597 2.88 4.41 2.80 6 475 6 643 2.75 2.70 13 681 13 540 118 393118 700 4.31 -0.18 4.13 6810 2.60 14 569 117 809
